WO2004031238A3 - Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics - Google Patents

Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics Download PDF

Info

Publication number
WO2004031238A3
WO2004031238A3 PCT/CA2003/001533 CA0301533W WO2004031238A3 WO 2004031238 A3 WO2004031238 A3 WO 2004031238A3 CA 0301533 W CA0301533 W CA 0301533W WO 2004031238 A3 WO2004031238 A3 WO 2004031238A3
Authority
WO
WIPO (PCT)
Prior art keywords
cea
relates
ceacam6
mediated
reversing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001533
Other languages
French (fr)
Other versions
WO2004031238A2 (en
Inventor
Clifford P Stanners
Christian Ilantzis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to AU2003278002A priority Critical patent/AU2003278002A1/en
Priority to EP03769082A priority patent/EP1554309A2/en
Priority to CA002500978A priority patent/CA2500978A1/en
Publication of WO2004031238A2 publication Critical patent/WO2004031238A2/en
Publication of WO2004031238A3 publication Critical patent/WO2004031238A3/en
Anticipated expiration legal-status Critical
Priority to US11/097,224 priority patent/US20060024314A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to differentiation and tumorigenicity. The present invention more particularly relates to ligands which target CEA and CEACAM6 such that the adhesion, differentiation-Inhibitory activities and tumorigenic effects of Ig superfamily members, CEA and CEACAM6, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents which reverse CEA-mediated tumorigenic effects by declustering CEA and CEACAM6. In one embodiment the invention relates to methods of reducing, preventing or reversing a CEA-mediated tumorigenic effect comprising a use of a CEA-mediated tumorigenic effect reducing CEA-declustering agent. In one embodiment, the invention relates to compositions and use thereof for reversing CEA-mediated tumorigenic effects on human cancer cells and uses thereof. In particular, the application relates to a monovalent CEA binding agent which interfereswith a CEA interaction responsible for a CEA-mediated tumorigenic effects, thereby minimizing or reversing same.
PCT/CA2003/001533 1998-02-12 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics Ceased WO2004031238A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003278002A AU2003278002A1 (en) 2002-10-03 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
EP03769082A EP1554309A2 (en) 2002-10-03 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
CA002500978A CA2500978A1 (en) 2002-10-03 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
US11/097,224 US20060024314A1 (en) 1998-02-12 2005-04-04 Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41552002P 2002-10-03 2002-10-03
US60/415,520 2002-10-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/097,224 Continuation US20060024314A1 (en) 1998-02-12 2005-04-04 Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics

Publications (2)

Publication Number Publication Date
WO2004031238A2 WO2004031238A2 (en) 2004-04-15
WO2004031238A3 true WO2004031238A3 (en) 2004-07-29

Family

ID=32069871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001533 Ceased WO2004031238A2 (en) 1998-02-12 2003-10-03 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics

Country Status (4)

Country Link
EP (1) EP1554309A2 (en)
AU (1) AU2003278002A1 (en)
CA (1) CA2500978A1 (en)
WO (1) WO2004031238A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
ES2524309T3 (en) * 2004-04-20 2014-12-05 Sphingotec Gmbh Use of tachykinin precursors and / or their fragments in medical diagnosis
MXPA06014065A (en) 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
PT2750713E (en) 2011-10-14 2016-01-20 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
ES2649990T3 (en) 2012-10-12 2018-01-16 Medimmune Limited Anti-CD22-pyrrolobenzodiazepine antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2738310T3 (en) 2012-10-12 2020-01-21 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (en) 2013-03-13 2018-11-13 麦迪穆有限责任公司 Pyrrolobenzodiazepines and their conjugates
JP6993084B2 (en) 2013-08-12 2022-02-03 ジェネンテック， インコーポレイテッド 1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound, and method of use and treatment
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
UA118113C2 (en) 2013-12-16 2018-11-26 Дженентек, Інк. Peptidomimetic compounds and antibody-drug conjugates thereof
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
TW201625688A (en) 2014-09-12 2016-07-16 建南德克公司 Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
EP3223854A1 (en) 2014-11-25 2017-10-04 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (en) 2014-12-03 2018-05-02 Genentech Inc Quaternary amine compounds and antibody-drug conjugates thereof.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
KR102111338B1 (en) 2015-10-02 2020-05-15 제넨테크, 인크. Pyrrolobenzodiazepine antibody drug conjugates and methods of use thereof
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (en) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 PROTAC antibody conjugates and methods of use thereof
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3496763B1 (en) 2016-08-11 2026-04-01 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
CN110536703B (en) 2017-04-20 2024-07-12 Adc治疗有限公司 Combination therapy using anti-AXL antibody-drug conjugates
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
RS62928B1 (en) 2017-08-18 2022-03-31 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (en) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (en) 2019-03-15 2024-05-06 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN117980327A (en) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 Specific conjugation of antibodies
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584368A1 (en) * 1992-02-14 1994-03-02 Suntory Limited Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same
WO1998025971A1 (en) * 1996-12-10 1998-06-18 Celltech Therapeutics Limited Monovalent antibody fragments
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
WO1999041370A1 (en) * 1998-02-12 1999-08-19 Mcgill University Cea/nca-based differentiation cancer therapy
WO2001074849A2 (en) * 2000-04-03 2001-10-11 Dyax Corp. Binding peptides for carcinoembryonic antigen (cea)
US20020052479A1 (en) * 1996-10-31 2002-05-02 Kerr W.H. Anderson High affinity humanized anit-cea monoclonal antibodies
WO2002076389A2 (en) * 2001-03-21 2002-10-03 The Trustees Of Boston University Compositions and methods to prevent metastasis from primary malignancies

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
EP0584368A1 (en) * 1992-02-14 1994-03-02 Suntory Limited Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same
US20020052479A1 (en) * 1996-10-31 2002-05-02 Kerr W.H. Anderson High affinity humanized anit-cea monoclonal antibodies
WO1998025971A1 (en) * 1996-12-10 1998-06-18 Celltech Therapeutics Limited Monovalent antibody fragments
WO1999041370A1 (en) * 1998-02-12 1999-08-19 Mcgill University Cea/nca-based differentiation cancer therapy
WO2001074849A2 (en) * 2000-04-03 2001-10-11 Dyax Corp. Binding peptides for carcinoembryonic antigen (cea)
WO2002076389A2 (en) * 2001-03-21 2002-10-03 The Trustees Of Boston University Compositions and methods to prevent metastasis from primary malignancies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUROKI M ET AL: "BIOCHEMICAL CHARACTERIZATION OF 25 DISTINCT CARCINOEMBRYONIC ANTIGEN (CEA) EPITOPES RECOGNIZED BY 57 MONOCLONAL ANTIBODIES AND CATEGORIZED INTO SEVEN GROUPS IN TERMS OF DOMAIN STRUCTURE OF THE CEA MOLECULE", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 11, no. 4, 1992, pages 391 - 407, XP000606978, ISSN: 0272-457X *
PEDLEY R B ET AL: "THE POTENTIAL FOR ENHANCED TUMOUR LOCALISATION BY POLY(ETHYLENE GLYCOL) MODIFICATION OF ANTI-CEA ANTIBODY", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 70, 1994, pages 1126 - 1130, XP000575990, ISSN: 0007-0920 *
TAHERI M. ET. AL.: "Identification of precise subdomains in carcinoembryonic antigen required for intracellular adhesion", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 35, September 2001 (2001-09-01), pages 26935 - 26943, XP002277780 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
AU2003278002A1 (en) 2004-04-23
AU2003278002A8 (en) 2004-04-23
CA2500978A1 (en) 2004-04-15
WO2004031238A2 (en) 2004-04-15
EP1554309A2 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
WO2002090566A3 (en) Recombinant tumor specific antibody and use thereof
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
EP2283868A3 (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
IL214325A (en) Anti-cmet antibody, composition comprising it and use thereof
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
AU2003278002A1 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
WO2005035572A3 (en) Antibody compositions and methods
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
WO2003083485A3 (en) Protein for use in hypoxia related conditions
WO2005116077A3 (en) LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY
GR3026219T3 (en) Mouse monoclonal antibodies
DE60018761D1 (en) THERAPEUTIC ANTIBODIES TO THE MUC-1 ANTIGEN AND METHOD FOR THEIR USE
WO1999049059A3 (en) Methods of cancer diagnosis using a chimeric toxin
WO2005016241A3 (en) Synthetic chemokine receptor ligands and methods of use thereof
MXPA05013667A (en) Dual component skin care compositions that comprise a self-tanning agent.
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
WO2004074437A3 (en) Compositions and methods for cancer immunotherapy
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2003054019A3 (en) Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2500978

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11097224

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003769082

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003769082

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11097224

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003769082

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP